engulfment and cell motility 3Genealiases: CED-12 · CED12 · ELMO-3
Q-omics provides the consensus-scored ELMO3 profile across patient tissues and cancer cell-line models. ELMO3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ELMO3 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ELMO3 RNA expression shows 17,782 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where ELMO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELMO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELMO3 survival associations across molecular data types. ELMO3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELMO3 RNA expression–survival associations across cancer types. High ELMO3 expression shows unfavorable associations in LUSC, UVM, PAAD, READ and HNSC, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for ELMO3 RNA expression.
This table summarizes ELMO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ELMO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELMO3 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, LUAD, THCA and LUSC. The BLCA box plot shows higher ELMO3 RNA expression in tumor versus normal tissue (log2 FC = +2.179, t-test p = .003).
This table shows molecular features associated with ELMO3 in patient tissues and cancer cell lines. In patient samples, ELMO3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ELMO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
